Focus: Penumbra is a publicly-traded medical device company focused on minimally invasive vascular and surgical devices for acute care interventions, primarily in stroke and thromboembolism. They operate at scale with $1.1B in FY2025 revenue and a market-leading position in mechanical thrombectomy.
Profile data last refreshed 4h ago · AI intelligence enriched 2w ago
Growing — net +12 jobs in 30d
49 jobs added vs 37 removed. Steady team buildout.
Ideal for commercial, operations, and quality roles in a growth-stage medical device company with strong cash generation; less suitable for scientists seeking deep R&D pipelines.
Flagship platform with multiple indications (stroke, ischemic stroke, general stroke) across 5+ pipeline programs; core revenue driver.
Help build intelligence for Penumbra
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Penumbra's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Multi-indication aspiration platform targeting venous and arterial thromboembolism; demonstrates platform expansion strategy.
Phase 2 trial underway for neurointerventional indication; addresses high-unmet-need aneurysm subtype.
Minimally-invasive endoscopy-guided approach to hemorrhage evacuation; represents innovation in hemorrhagic stroke.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo